Answers are grounded in this paper and cite their sources.
Immune checkpoint inhibitor related pituitary toxicity (pituitary irAE) remains a relatively common complication of treatment which has transformed prognosis in several solid organ malignancies. While it may present with clear and clinically significant adrenal insufficiency, diagnostic uncertainty can remain due its potentially subtle clinical phenotype and symptom overlap with other treatment related effects. Currently pituitary irAE lacks a validated biomarker or single unifying pathophysiological model. This review aims to outline what is known regarding pathogenesis, presentation, biomarkers and long-term outcomes of pituitary irAE to inform future directions and priorities for care and research. Emerging data suggest multiple plausible immune pathways, including activation of pre-existing autoimmunity, direct checkpoint-mediated pituitary toxicity, paraneoplastic immune responses and cytokine-driven injury, but these mechanisms likely vary between patients. This review also explores current and future clinical priorities for hormone replacement, patient education and ongoing endocrine follow-up. As survival improves for patients receiving immune checkpoint inhibitors, improved phenotyping, biomarker development and long-term outcomes research will be essential to refine diagnosis, prognostication and survivorship care.
No takes yet. Share an insight, caveat, or question.
Hayes et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: